Peak Strength Bio
Research Use Only: For research use only. Not for human consumption. Content is educational and is not medical advice, diagnosis, or treatment.
Peptides / Other / Fat Loss

SLU-PP-332

Selective Estrogen-Related Receptor (ERR) Agonist

SLU-PP-332

SLU-PP-332 is a novel, selective estrogen-related receptor (ERR) agonist with primary affinity for the ERRα subtype. Preclinical studies suggest it acts as an exercise mimetic, enhancing mitochondrial biogenesis, oxidative capacity, and fatty acid metabolism in energetic tissues.

Typical dose
Predominantly evaluated in animal models (e.g., 25–50 mg/kg in rodents); research assays explore various microgram-range concentrations depending on protocol.
Half-life
Undetermined in humans; preclinical animal pharmacokinetic profiles indicate short systemic clearance.
Administration
Intraperitoneal (IP) injection, oral gavage (animal models), or in vitro media suspension.
Research status
Preclinical / research use only
Calculate a dose

What it is

SLU-PP-332 is an estrogen-related receptor (ERR) agonist studied in preclinical models as an exercise mimetic — activating pathways associated with endurance, mitochondrial biogenesis, and fat oxidation.

Why researchers use it

  • Promotes fat oxidation without stimulant load
  • Enhances endurance-related gene expression in animal models
  • Studied as a complement to GLP-1 fat-loss stacks

Dosing protocol (for research)

  • Oral capsule/tablet form
  • Typical range: 50–250 mcg per protocol
  • Best taken before training on active days

Safety notes

  • Preclinical data only; human safety profile is not established
  • Avoid stacking with other stimulant-heavy compounds in research settings

Reconstitution & concentration

Supplied as an oral capsule — no reconstitution required. Typical capsule: 250 mcg.

  • Research protocols often test 250–500 mcg daily, adjusted for tolerance
  • Duration: 4–8 weeks in metabolic studies

Note: that overuse risks excessive mitochondrial uncoupling — fatigue, overheating, or metabolic strain — and recommends careful titration and monitoring.

Stacks

  • Metabolic Accelerator Stack: Retatrutide 4–12 mg/week (SubQ) + SLU-PP-332 250–500 mcg daily (oral), 12–16 weeks
  • Balanced Fat-Loss Blend: Tirzepatide 5–10 mg/week + SLU-PP-332 250 mcg daily + BAM15 50 mcg daily, 12–16 weeks
  • Metabolic Drive Stack: SLU-PP-332 250 mcg daily + NAD+ 250–500 mg IM weekly

Research notes the SLU/BAM pairing is often capped at 250 mcg SLU-PP-332 + 50 mcg BAM15 as a safe 'sweet spot'.

Where to source